Item 1.01. Entry into a Material Definitive Agreement
On January 19, 2022, certain subsidiaries of Maravai LifeSciences Holdings, Inc.
(the "Company") entered into Amendment No. 2 (the "Amendment") to the Credit
Agreement, dated as of October 19, 2020, among Maravai Intermediate Holdings,
LLC, Cygnus Technologies, LLC and Trilink Biotechnologies, LLC, as the
borrowers, Maravai Topco Holdings, LLC, as holdings, the lenders from time to
time party thereto and Morgan Stanley Senior Funding, Inc., as administrative
and collateral agent (as amended, supplemented or otherwise modified, the
"Credit Agreement"). The Amendment replaces the LIBOR (London Interbank Offered
Rate) based interest rate with a Term SOFR (Secured Overnight Financing Rate)
based rate. The Amendment also reduces the interest rate margins applicable to
the term and revolving facilities under the Credit Agreement. The previous
interest rate margin on the facilities was, with respect to each LIBOR-based
loan, 3.75% to 4.25% and, with respect to each base rate-based loan, 2.75% to
3.25% (depending, in each case, on consolidated first lien leverage). Following
the Amendment, the interest rate margin on the facilities is 3.00%, with respect
to each Term SOFR-based loan, and 2.00%, with respect to each base rate-based
loan. Further, the Amendment reduces the base rate floor for the term loans from
2.00% to 1.50%, sets the floor for Term SOFR-based term loans at 0.50% and sets
the floor for Term SOFR-based revolving loans at 0.00%. No other significant
terms under the Credit Agreement were changed in connection with the Amendment.
The foregoing description of the Amendment does not purport to be complete and
is qualified in its entirety by reference to the full text of the Amendment, a
copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are furnished as part of this Current Report on Form 8-K:

     Exhibit No.             Description of Exhibit
                               Amendment No. 2, dated as of January 19,

2022, to the Credit Agreement,


         10.1                dated as of October 19, 2020, among Maravai

Intermediate Holdings, LLC,

Cygnus Technologies, LLC, Trilink

Biotechnologies, LLC, Maravai Topco

Holdings, LLC and Morgan Stanley Senior Funding, Inc.
         104                 Cover Page Interactive Data File (embedded within the Inline XBRL
                             document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses